about
Cabergoline for preventing ovarian hyperstimulation syndromeCabergoline for preventing ovarian hyperstimulation syndromeCooperation between integrin alphavbeta3 and VEGFR2 in angiogenesisRole of receptor tyrosine kinases in gastric cancer: new targets for a selective therapyPTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationHyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia.A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration.Dopamine agonists for preventing ovarian hyperstimulation syndrome.Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathwayDietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis.Emerging drugs for the treatment of myelodysplastic syndrome.A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.Clinical utilization of chemokines to combat cancer: the double-edged sword.Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.The Current and Future Therapies for Human Osteosarcoma.Sprouty4 regulates endothelial cell migration via modulating integrin β3 stability through c-Src.Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).Drug resistance associated with antiangiogenesis therapy.Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.Recent advances in delivery of drug-nucleic acid combinations for cancer treatmentZinc finger MYND-type containing 8 promotes tumour angiogenesis via induction of vascular endothelial growth factor-A expression.Development of cholesteryl peptide micelles for siRNA delivery.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab.Cloning and expression of human vascular endothelial growth factor gene and inhibition of its expression by antisense in prokaryotic system.Multimodal cancer treatment: real time monitoring, optimization, and synergistic effects.Advanced alveolar soft part sarcoma responds to apatinib.Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature reviewA novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report.A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers.Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry.
P2860
Q24203638-8DB78B8D-E9D4-4C35-BE6B-7515BB49DE86Q24234591-22561413-9B75-4FA3-A2CD-F587C8BBFD41Q24318607-415C4C0F-5D16-4EEC-8052-23234D784BCFQ28242840-E9B98B2E-143A-4D8D-B144-4EEFE35E72C5Q28378001-63030E0C-2F6A-4E02-8BD1-EBC2697A8976Q30784823-D09AC8FB-B7EC-4064-A19B-2FE1D09B7CA5Q33433070-C5A109F3-0FEF-40D1-9DC1-D60263038A56Q34493854-9F2936D9-4DCD-4D0A-AD61-09E039421A32Q34546236-4BF443CF-D957-4192-80CB-CEE435DAD0FFQ35210298-E055AC9D-C84D-4359-AF67-3DBE1CF55F80Q35766830-44069CBC-FD8C-467E-8A1F-0B8EB3FFE1A9Q36219655-DC1B6F87-DA0B-4201-885C-FCFA6BA0DF76Q36449359-C215D61C-557A-4EB2-8864-69D4375B3175Q36488894-FF48EDD2-E189-4F0F-9390-0C4CA6289770Q36494268-21106589-0169-4BDC-AEA2-938A94C50E47Q36514299-069B6C2F-3F8F-4CEA-B72A-15E0DF018FF1Q37214746-E270F9D7-74E9-4104-9A8E-0FD318B33145Q37329315-9A154869-0EB0-4773-A3F4-82B78167375AQ37518288-F97686C9-A397-456C-A02A-EE1FA85B6801Q37707033-4A482233-FD18-4DDE-88F8-DE23B1CBF80FQ38056538-9D951B39-B163-4602-B616-6C9721B93FECQ38102522-F958A608-AA02-413A-9F0B-62B1CDD8229CQ38966676-D222EFB9-69DB-4B94-BEEE-467699C38404Q39106589-5F211867-975A-4F92-87A8-E35C5AE543CEQ39569400-2C0A5D5E-F40A-4CFB-974F-569979EB7E6DQ39616746-7D81BE5E-75AE-4828-9B27-80EB04ED1A43Q39757470-A2B99E7A-5924-4AB9-9E8A-0609B0AEC2BFQ39941336-1574E298-2050-4081-9E3C-944687A0151AQ41473058-D5189D43-15FE-4D4F-BCAA-47FE95D3CB4DQ41915464-985DC6C0-89C4-4179-AA39-127D77CDE87BQ42497254-23C54412-2F2D-4E54-A8A6-660824388C7BQ45771543-8577E6C0-C596-4AC0-9AF9-D4E10AC95F2CQ47115888-FECD340C-4BD3-4412-9D6D-3D4A1B80A09DQ48090720-9873D4B5-1916-4003-98FF-2965BD2A4EE3Q54999095-B6DF1BEC-5F26-443E-A9C3-7618BAFCCB1B
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
VEGF blocking therapy in the treatment of cancer.
@ast
VEGF blocking therapy in the treatment of cancer.
@en
type
label
VEGF blocking therapy in the treatment of cancer.
@ast
VEGF blocking therapy in the treatment of cancer.
@en
prefLabel
VEGF blocking therapy in the treatment of cancer.
@ast
VEGF blocking therapy in the treatment of cancer.
@en
P2093
P2860
P356
P1476
VEGF blocking therapy in the treatment of cancer.
@en
P2093
Darrell J Yamashiro
Jessica J Kandel
Julia Glade-Bender
P2860
P304
P356
10.1517/14712598.3.2.263
P407
P577
2003-04-01T00:00:00Z